Welcome to our dedicated page for Chromadex news (Ticker: CDXC), a resource for investors and traders seeking the latest updates and insights on Chromadex stock.
About Chromadex Corp
Chromadex Corp (CDXC) is a globally recognized integrated nutraceutical and bioscience company committed to improving the quality of life through advanced research on healthy aging. The company is deeply invested in understanding the mechanisms by which cellular processes, particularly those involving nicotinamide adenine dinucleotide (NAD+), impact the aging process. With a core focus on innovative science, Chromadex has developed a multifaceted business model that spans from research breakthroughs to commercially available consumer products, ensuring that its scientific discoveries translate into meaningful daily benefits.
Business Model and Core Segments
Chromadex’s operational framework is built on three primary segments that work in unison to deliver high-quality, science-based nutraceutical innovations:
- Consumer Products: This segment is primarily responsible for marketing and distributing products directly to the consumer market. Its portfolio features formulations designed to support healthy aging by leveraging proprietary, scientifically validated ingredients. The company’s flagship product, built around the NAD+ precursor nicotinamide riboside (NR), exemplifies its commitment to translating rigorous research into everyday solutions.
- Ingredients Segment: Focused on the development and licensing of novel ingredients, this segment utilizes high-caliber scientific research to create bioactive compounds. These innovations are targeted for use in various applications, ranging from dietary supplements to functional foods, ensuring that the expertise of Chromadex is shared widely across the industry.
- Analytical Reference Standards and Services: This area underpins the rigorous quality control and analytical validation processes that are crucial to research and product development. By offering specialized standards and services, Chromadex supports both internal development and external quality assurance needs in a scientifically robust manner.
Research and Innovation
At the heart of Chromadex’s operations is a steadfast commitment to research and development. The company partners with leading universities and research institutions worldwide to explore the potential of critical biochemical pathways related to aging. This collaborative approach not only strengthens its research capabilities but also ensures that the ingredients developed are based on solid scientific evidence. The integration of cutting-edge bioscience and precise analytical methodologies solidifies its position as a trusted name in the nutraceutical industry.
Market Position and Competitive Differentiation
Chromadex distinguishes itself by focusing on the intersection of scientific innovation and consumer wellness. Its emphasis on NAD+ research, an area that has increasingly become synonymous with the study of aging and cellular health, sets it apart in a competitive landscape that includes various bioscience and nutraceutical companies. The company’s multidimensional approach, which bridges direct consumer engagement with deep scientific inquiry, provides a unique value proposition that caters both to health-conscious individuals and to industry partners seeking high-quality, science-backed ingredients.
Commitment to Transparency and Quality
Transparency in research and product development is a core tenet of Chromadex’s philosophy. Every stage of its process—from initial scientific exploration to the final formulation—undergoes rigorous analytical review and quality control. This disciplined approach reassures consumers and industry collaborators alike, fostering trust and establishing Chromadex as a reliable source of scientifically supported nutraceutical innovations.
Integrating Science and Consumer Wellness
The company’s approach is marked by a detailed understanding of biochemical processes and a commitment to translating this expertise into practical health solutions. With its diversified business segments, Chromadex not only addresses the needs of a broad consumer base but also solidifies its reputation among researchers and industry experts. Its dedicated exploration of key ingredients such as nicotinamide riboside, alongside other innovative compounds, continues to influence the realm of healthy aging and functional nutrition.
ChromaDex Corp. (NASDAQ: CDXC) has published Phase 3 study results demonstrating that a nutritional protocol can reduce recovery time in mild-to-moderate COVID-19 patients by 3.5 days. Conducted at Umraniye Teaching and Research Hospital in Turkey, this double-blind trial included 309 participants and assessed the effectiveness of nicotinamide riboside (NR) and other active ingredients. The findings also indicated improved liver health and reduced inflammatory markers, supporting the potential of these metabolic activators in enhancing recovery.
ChromaDex Corp. (NASDAQ: CDXC) has announced a securities purchase agreement for a private placement of $25 million in common stock. The placement involves selling 3,846,153 shares at $6.50 each, led by a new international investor, with expected closure by February 23, 2021. The funds will enhance the growth of its flagship product, Tru Niagen®, and support clinical research on NAD+ precursors. ChromaDex will enter a registration rights agreement and assures these shares are not registered under the Securities Act of 1933.
ChromaDex Corp. (NASDAQ:CDXC) will host a conference call on March 10, 2021, at 4:30 p.m. ET to discuss its fourth-quarter financial results for the period ending December 31, 2020. The results will be announced in a press release after market close. Interested participants should dial in 10 minutes prior. The toll-free and international numbers are provided in the announcement. A replay of the call will be available post-event. ChromaDex focuses on nutraceuticals and is known for its NIAGEN® ingredient, aimed at improving health as people age.
ChromaDex Corp. (NASDAQ: CDXC) announced positive results from a Phase 2 study on the effects of a nutritional protocol involving nicotinamide riboside (NR) on non-alcoholic fatty liver disease (NAFLD). The study demonstrated a significant 10% reduction in liver fat and 39% decrease in serum ALT levels among 31 overweight or obese participants. Conducted with the ChromaDex External Research Program, the findings suggest that metabolic cofactor supplementation may enhance liver health. ChromaDex has invested over $35 million in NR research and holds more than 20 patents related to its use.
ChromaDex Corp. (NASDAQ: CDXC) will present at the Benzinga Small Cap Conference on December 9, 2020, at 11:15 AM ET. This virtual event aims to connect small-cap companies with investors and traders, featuring networking and educational opportunities. ChromaDex will have a presentation available for replay on its investor relations website following the event. The company specializes in nutraceuticals, focusing on improving aging through its flagship ingredient, NIAGEN®.
ChromaDex Corp. (NASDAQ:CDXC) has launched a clinical trial at the University of California, Davis, investigating the effects of Niagen® (nicotinamide riboside) on milk production in preterm mothers. Following positive preclinical results, the double-blinded study will assess milk production and metabolic markers among 32 participants over 14 days. Previously, NR supplementation increased milk production in rodent studies, with potential benefits for both mothers and their newborns. ChromaDex has invested over $35 million in Niagen research and marketing, aimed at exploring its health benefits.
ChromaDex Corp. (NASDAQ:CDXC) has launched its exclusive TRU NIAGEN® EX Stick Packs in collaboration with Watsons Hong Kong, available both online and in stores. TRU NIAGEN® has been the best-selling supplement at Watsons, and the new stick packs provide an alternative delivery method for this healthy aging vitamin. Each pack contains 300mg of nicotinamide riboside, aiming to appeal to fitness-focused consumers. The partnership, ongoing since 2017, broadens the product's accessibility to health-conscious customers.
ChromaDex (Nasdaq: CDXC) reported Q3 2020 net sales of $14.2 million, an 18% increase from the previous year. Tru Niagen® sales reached $11.9 million, up 22%. The net loss improved to ($4.2) million or ($0.07) per share, compared to ($7.2) million in Q3 2019. Adjusted EBITDA loss was ($0.1) million, a $1.7 million improvement year-over-year. The company anticipates continued revenue growth from its e-commerce and international markets, alongside improved gross margins.
ChromaDex Corp. (NASDAQ:CDXC) will hold a conference call on November 4, 2020, at 4:30 p.m. ET to discuss its financial results for Q3 2020, ending September 30. This call will follow the release of their earnings report, which will be shared after market close on the same day. Investors wishing to participate should dial in 10 minutes early. A replay will be available post-call. ChromaDex is focused on developing nutraceuticals, notably its flagship ingredient, NIAGEN®, aimed at enhancing human health.
ChromaDex Corp. (NASDAQ:CDXC) has highlighted a groundbreaking study published in The European Molecular Biology Organization Journal on nicotinamide riboside (NR) and its role in maintaining telomeres, critical for DNA integrity. Conducted by the National Institute on Aging and the National Cancer Institute, this study shows NR's potential in raising NAD+ levels, protecting telomeres, and possibly aiding in the fight against age-related diseases. ChromaDex provided NR via its External Research Program, while the study underscores the need for further research into NR's benefits.
FAQ
What is the current stock price of Chromadex (CDXC)?
What is the market cap of Chromadex (CDXC)?
What is Chromadex Corp's primary focus?
How does Chromadex generate its revenue?
What makes Chromadex's research unique?
What is the significance of nicotinamide riboside (NR) for Chromadex?
In which segments does Chromadex operate?
How does Chromadex ensure the quality and safety of its products?
How is Chromadex positioned within the competitive landscape?
What are the key benefits of Chromadex's integrated business model?
